From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
May 8, 2025 at 1PM EST
The pharmaceutical landscape is undergoing a profound transformation, marked by significant regulatory shifts and the imperative for enhanced cross-functional effectiveness. This webinar will provide a comprehensive analysis of the impact of 340B regulations and the Inflation Reduction Act (IRA) on pharmaceutical revenue and pricing strategies. We’ll explore the intricacies of these legislative changes and their implications for manufacturers and healthcare providers.
• Understand the financial implications of the 340B and IRA regulations.
• Analyze product archetypes to inform strategic business decisions.
• Develop effective pricing strategies in a changing regulatory environment.
• Enhance cross-functional collaboration to maximize impact.
Learn how to connect the dots and make informed decisions in today’s complex landscape.
Jen SharpeVice President, GTN Advisory
Walt WorshamManaging Director
